Sanofi: start of licensing agreement with Innate Pharma
Sanofi has also acquired an option to add up to two additional targets from Innate's ANKET platform. Following the selection of each drug candidate, it will be responsible for product development, manufacturing and commercialization.
Under the terms of the agreement, Innate will receive an upfront payment of 25 million euros and up to 1.35 billion euros in milestone payments linked to the achievement of targets, as well as royalties on potential net sales.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction